论文部分内容阅读
目的探讨高强度聚焦超声系统(HIFU)治疗局限性前列腺癌的有效性及安全性。方法使用Sonablate-500聚焦超声系统对26例局限性前列腺癌患者进行治疗,观察术后3、6、12个月时的血清前列腺特异性抗原(PSA)、直肠指诊及经直肠B超情况。结果平均手术操作时间48min(28～86min),平均术后住院时间3.2d(2～9d)。治疗后3、6、12个月PSA与治疗前相比有显著降低(P<0.05),直肠指诊发现结节消失或减小的占73.3%(11/15),B超提示:低回声结节消失或缩小的占76.9%(20/26)。治疗后3、6、12个月各项检查结果经统计学检验无显著性差异。结论HIFU可以安全、有效杀死前列腺癌细胞,在治疗局限性前列腺癌方面具有美好的应用前景。
Objective To investigate the efficacy and safety of high intensity focused ultrasound (HIFU) in the treatment of localized prostate cancer. Methods Twenty-six patients with localized prostate cancer were treated with the Sonablate-500 focused ultrasound system. Serum PSA, digital rectal examination and transrectal B-ultrasound were performed at 3, 6 and 12 months after operation. Results The average operation time was 48min (28 ~ 86min), the average postoperative hospital stay was 3.2d (2 ~ 9d). At 3, 6 and 12 months after treatment, PSA was significantly lower than that before treatment (P <0.05), and 73.3% (11/15) of the nodules disappeared or decreased in the digital rectal examination. Nodules disappeared or reduced 76.9% (20/26). 3,6,12 months after treatment, the results of the inspection by the statistical test showed no significant difference. Conclusion HIFU can safely and effectively kill prostate cancer cells and has a bright future in the treatment of localized prostate cancer.